Thermo Fisher Scientific Inc. $TMO Shares Purchased by Thomasville National Bank

Key Points

• Thomasville National Bank increased its stake in Thermo Fisher Scientific by 73% to a total of 34,529 shares, valued at approximately $14 million.
• Multiple analysts have adjusted their price targets for Thermo Fisher, with an average target of $588.35 and a consensus rating of "Moderate Buy".
• The company reported $10.86 billion in revenue for its last quarter, exceeding expectations and marking a 2.9% year-over-year increase in earnings per share.

Thomasville National Bank lifted its position in shares of Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 73.0% in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 34,529 shares of the medical research company's stock after acquiring an additional 14,573 shares during the period. Thomasville National Bank's holdings in Thermo Fisher Scientific were worth $14,000,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors and hedge funds also recently made changes to their positions in TMO. Bernard Wealth Management Corp. bought a new stake in shares of Thermo Fisher Scientific during the 4th quarter worth approximately $25,000. CBIZ Investment Advisory Services LLC raised its stake in shares of Thermo Fisher Scientific by 137.5% during the first quarter. CBIZ Investment Advisory Services LLC now owns 57 shares of the medical research company's stock valued at $28,000 after acquiring an additional 33 shares during the last quarter. Ameriflex Group Inc. acquired a new stake in shares of Thermo Fisher Scientific during the fourth quarter worth $30,000. Anderson Financial Strategies LLC acquired a new stake in Thermo Fisher Scientific in the first quarter worth $30,000. Finally, Keystone Global Partners LLC bought a new position in shares of Thermo Fisher Scientific in the first quarter valued at $31,000. Institutional investors own 89.23% of the company's stock.

Thermo Fisher Scientific Stock Down 1.1%

Shares of NYSE TMO traded down $5.04 during midday trading on Monday, hitting $474.54. 2,340,065 shares of the company's stock were exchanged, compared to its average volume of 2,394,316. The company has a debt-to-equity ratio of 0.65, a current ratio of 1.93 and a quick ratio of 1.50. Thermo Fisher Scientific Inc. has a twelve month low of $385.46 and a twelve month high of $623.77. The company has a market cap of $179.19 billion, a PE ratio of 27.45, a P/E/G ratio of 2.56 and a beta of 0.75. The firm's fifty day simple moving average is $472.01 and its 200-day simple moving average is $448.95.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last released its quarterly earnings results on Wednesday, July 23rd. The medical research company reported $5.36 EPS for the quarter, topping the consensus estimate of $5.22 by $0.14. The company had revenue of $10.86 billion for the quarter, compared to analyst estimates of $10.68 billion. Thermo Fisher Scientific had a return on equity of 16.82% and a net margin of 15.24%.The firm's revenue was up 2.9% compared to the same quarter last year. During the same quarter in the previous year, the company posted $5.37 earnings per share. Thermo Fisher Scientific has set its Q3 2025 guidance at 5.460-5.510 EPS. FY 2025 guidance at 22.220-22.840 EPS. Research analysts predict that Thermo Fisher Scientific Inc. will post 23.28 EPS for the current fiscal year.

Thermo Fisher Scientific Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Wednesday, October 15th. Shareholders of record on Monday, September 15th will be given a dividend of $0.43 per share. The ex-dividend date of this dividend is Monday, September 15th. This represents a $1.72 annualized dividend and a yield of 0.4%. Thermo Fisher Scientific's payout ratio is 9.95%.

Wall Street Analysts Forecast Growth

A number of research analysts recently weighed in on the stock. Royal Bank Of Canada set a $561.00 price target on shares of Thermo Fisher Scientific and gave the company an "outperform" rating in a research report on Tuesday, September 2nd. Raymond James Financial reaffirmed an "outperform" rating and issued a $535.00 price objective (up previously from $525.00) on shares of Thermo Fisher Scientific in a research note on Thursday, July 24th. Evercore ISI lowered their price target on shares of Thermo Fisher Scientific from $500.00 to $480.00 and set an "outperform" rating for the company in a report on Tuesday, July 8th. Wells Fargo & Company reduced their target price on shares of Thermo Fisher Scientific from $570.00 to $565.00 and set an "overweight" rating on the stock in a research report on Thursday, July 24th. Finally, HSBC reissued a "hold" rating and set a $510.00 price objective on shares of Thermo Fisher Scientific in a research report on Thursday, July 24th. Sixteen analysts have rated the stock with a Buy rating and five have given a Hold rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and an average target price of $588.35.

Insider Activity

In other news, EVP Gianluca Pettiti sold 400 shares of the business's stock in a transaction that occurred on Friday, July 25th. The stock was sold at an average price of $479.98, for a total value of $191,992.00. Following the transaction, the executive vice president owned 22,367 shares of the company's stock, valued at approximately $10,735,712.66. The trade was a 1.76% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CAO Joseph R. Holmes sold 385 shares of the business's stock in a transaction that occurred on Friday, August 29th. The shares were sold at an average price of $492.63, for a total value of $189,662.55. Following the completion of the transaction, the chief accounting officer directly owned 2,319 shares in the company, valued at approximately $1,142,408.97. The trade was a 14.24% decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 30,066 shares of company stock valued at $14,182,963. Company insiders own 0.33% of the company's stock.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.